Of 10 high-expenditure drugs that had substantial 2022 net price increases, eight were not supported by new clinical evidence; these increases accounted for $1.27 billion in additional costs over one year. Separately, one of three Medicare Part B drugs with high list price increases in 2021 lacked adequate supporting new evidence, directly raising annual out-of-pocket expenses for Medicare patients by up to $680 per year.

Final Documents

For questions or additional information, please contact info@icer.org.

ICER’s Chief Medical Officer David Rind, MD:

“We continue to see list price increases above inflation for many of the most costly drugs. When we look further at those drugs whose net price increases led to the largest increases in US expenditures, many had no substantial new evidence to support such price increases. Additionally, list price increases can present real hardships to patients who must pay deductibles or coinsurance.”